A pivotal trial of GLPG1690 in Idiopathic Pulmonary Fibrosis (IPF) : ISABELA 1

Trial Profile

A pivotal trial of GLPG1690 in Idiopathic Pulmonary Fibrosis (IPF) : ISABELA 1

Planning
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs GLPG 1690 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ISABELA 1
  • Sponsors Galapagos NV
  • Most Recent Events

    • 12 Apr 2018 According to a Galapagos NV media release, this ISABELA program is expected to start dosing in the second half of 2018. A total of 1500 patients are planned to enrol in this program.
    • 12 Apr 2018 According to a Galapagos NV media release, based on feedback from the FDA and EMA, company announces the design of this study. The ISABELA Phase 3 program is intended to support the New Drug Application (NDA) and the Market Authorization Application (MAA) submissions in respectively the USA and EU for GLPG1690 in Idiopathic Pulmonary Fibrosis (IPF).
    • 27 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top